The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Lanari, Marcello ^a   Vandini, Silvia ^b   Arcuri, Santo ^b   Galletti, Silvia ^b   Faldella, Giacomo ^b  

^a Imola Hospital   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FELVIZUMAB; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; MOTAVIZUMAB; PALIVIZUMAB; PLACEBO; ANTIVIRUS AGENT;

CHRONIC LUNG DISEASE; CONJUNCTIVITIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CYANOSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; INJECTION SITE REACTION; MORTALITY; NERVOUSNESS; NEUROMUSCULAR DISEASE; NONHUMAN; PREMATURITY; PRIORITY JOURNAL; RASH; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RISK FACTOR; SIDE EFFECT; ADULT; CLINICAL TRIAL (TOPIC); CONGENITAL HEART MALFORMATION; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; INFANT; NEWBORN; PRESCHOOL CHILD; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SURVIVAL; VIROLOGY; DRUG EFFECTS; HEART DEFECTS, CONGENITAL; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFANT, PREMATURE, DISEASES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HEART DEFECTS, CONGENITAL; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; SURVIVAL ANALYSIS;

EID: 84880181089     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/359683     Document Type: Review

References (76)

1. Chanock R., Roizman B., Myers R., Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA)-part 1, isolation, properties and characterization. American Journal of Epidemiology 1957 66 3 281 290 2-s2.0-77957183481
2. Martinello R. A., Chen M. D., Weibel C., Kahn J. S., Correlation between respiratory syncytial virus genotype and severity of illness. Journal of Infectious Diseases 2002 186 6 839 842 2-s2.0-0037105638 10.1086/342414 (Pubitemid 35013438)
3. Gilca R., De Serres G., Tremblay M., Vachon M.-L., Leblanc E., Bergeron M. G., Déry P., Boivin G., Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons. Journal of Infectious Diseases 2006 193 1 54 58 2-s2.0-29744445107 10.1086/498526 (Pubitemid 43032499)
4. Simoes E. A. F., Respiratory syncytial virus infection. Lancet 1999 354 9181 847 852 2-s2.0-0033523417 10.1016/S0140-6736(99)80040-3 (Pubitemid 29415599)
5. Boyce T. G., Mellen B. G., Mitchel E. F. Jr., Wright P. F., Griffin M. R., Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. Journal of Pediatrics 2000 137 6 865 870 2-s2.0-0033638924 10.1067/mpd.2000.110531
6. Leader S., Kohlhase K., Pearlman M. H., Williams J. V., Engle W. A., Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. Journal of Pediatrics 2003 143 5, supplement S127 S132 2-s2.0-0344153462 (Pubitemid 37456910)
7. Paramore L. C., Ciuryla V., Ciesla G., Liu L., Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. PharmacoEconomics 2004 22 5 275 284 2-s2.0-2142657849 10.2165/00019053-200422050-00001 (Pubitemid 38553698)
8. Thompson W. W., Shay D. K., Weintraub E., Brammer L., Cox N., Anderson L. J., Fukuda K., Mortality associated with influenza and respiratory syncytial virus in the United States. Journal of the American Medical Association 2003 289 2 179 186 2-s2.0-0037425564 10.1001/jama.289.2.179 (Pubitemid 36068705)
9. Nair H., Verma V. R., Theodoratou E., Zgaga L., Huda T., Simões E. A., Wright P. F., Rudan I., Campbell H., An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children. BMC Public Health 2011 11 3, supplement, article S30 2-s2.0-79954567948 10.1186/1471-2458-11-S3-S30
10. Hall C. B., Weinberg G. A., Iwane M. K., Blumkin A. K., Edwards K. M., Staat M. A., Auinger P., Griffin M. R., Poehling K. A., Erdman D., Grijalva C. G., Zhu Y., Szilagyi P., The Burden of respiratory syncytial virus infection in young children. New England Journal of Medicine 2009 360 6 588 598 2-s2.0-59749095702
11. Shay D. K., Holman R. C., Newman R. D., Liu L. L., Stout J. W., Anderson L. J., Bronchiolitis-associated hospitalizations among US children, 1980-1996. Journal of the American Medical Association 1999 282 15 1440 1446 2-s2.0-0032696770 10.1001/jama.282.15.1440 (Pubitemid 29493797)
12. Welliver R. C., Willison D. F., Scott C. A., Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. Journal of Pediatrics 2003 143 5, supplement S112 S117 2-s2.0-0344585033 (Pubitemid 37456908)
13. Resch B., Manzoni P., Lanari M., Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatric Respiratory Reviews 2009 10 3 148 153 2-s2.0-67849084667 10.1016/j.prrv.2009.06.003
14. Simoes E. A. F., Immunoprophylaxis of respiratory syncytial virus infection. Indian Pediatrics 2000 37 3 243 247 2-s2.0-0034102721 (Pubitemid 30164507)
15. Wang E. E. L., Law B. J., Stephens D., Pediatric investigators collaborative network on infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. Journal of Pediatrics 1995 126 2 212 219 2-s2.0-0028984727 10.1016/S0022-3476(95)70547-3
16. Figueras-Aloy J., Carbonell-Estrany X., Quero J., Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatric Infectious Disease Journal 2004 23 9 815 820 2-s2.0-6344280211 10.1097/01.inf.0000136869.21397.6b (Pubitemid 40221022)
17. Lanari M., Giovannini M., Giuffré L., Marini A., Rondini G., Rossi G. A., Merolla R., Zuccotti G. V., Salvioli G. P., Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Pediatric Pulmonology 2002 33 6, supplement 458 465 2-s2.0-18444387677 10.1002/ppul.10047 (Pubitemid 34547867)
18. Lanari M., Adorni F., Silvestri M., Coscia A., Musicco M., The multicenter Italian birth cohort study on incidence and determinants of lower respiratory tract infection hospitalization in infants at 33weeks GA or more: preliminary results. Early Human Development 2011 87, supplement S43 S46 2-s2.0-79951851987 10.1016/j.earlhumdev.2011.01.009
19. Liese J. G., Grill E., Fischer B., Roeckl-Wiedmann I., Carr D., Belohradsky B. H., Münch G., Simbruner G., Küster H., Lipowsky G., Schulze A., Genzel O., Roos R., Grimberg B., Zimmermann A., Der Isar K. R., Engelsberger I., Peters J., Kumlien B., Daunderer D., John W., Peller P., Andrian H. C., Schenk W., Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. European Journal of Pediatrics 2003 162 4 230 236 2-s2.0-0037387758 (Pubitemid 36437755)
20. Sampalis J. S., Williams J. V., Morbidity and mortality after RSV-associated hospitalizations among premature canadian infants. Journal of Pediatrics 2003 143 5, supplement S150 S156 2-s2.0-0345447184 (Pubitemid 37456913)
21. Simoes E. A. F., Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. Journal of Pediatrics 2003 143 5, supplement S118 S126 2-s2.0-0345016005 (Pubitemid 37456909)
22. Weigl J. A. I., Puppe W., Schmitt H.-J., Can respiratory syncytial virus etiology be diagnosed clinically? A hospital-based case-control study in children under two years of age. European Journal of Epidemiology 2003 18 5 431 439 2-s2.0-0037484504 10.1023/A:1024213400297 (Pubitemid 36859307)
23. Baraldi E., Filippone M., Chronic lung disease after premature birth. New England Journal of Medicine 2007 357 19 1946 1955 2-s2.0-35848952935 10.1056/NEJMra067279 (Pubitemid 350074689)
24. Lanari M., Rossi G. A., Merolla R., Di Luzio Paparatti U., Feltes T. F., High risk of nosocomial-acquired RSV infection in children with congenital heart disease. Journal of Pediatrics 2004 145 1 140 141 2-s2.0-3242688982 10.1016/j.jpeds.2004.03.029 (Pubitemid 38962469)
25. Zachariah P., Ruttenber M., Simões E. A. F., Down syndrome and hospitalizations due to respiratory syncytial virus: a population-based study. Journal of Pediatrics 2012 160 5 827 831 2-s2.0-84859923496 10.1016/j.jpeds. 2011.11.004
26. Luján-Zilbermann J., Benaim E., Tong X., Srivastava D. K., Patrick C. C., DeVincenzo J. P., Respiratory virus infections in pediatric hematopoietic stem cell transplantation. Clinical Infectious Diseases 2001 33 7 962 968 2-s2.0-0035478883 10.1086/322628 (Pubitemid 32907096)
27. Panitch H. B., Bronchiolitis in infants. Current Opinion in Pediatrics 2001 13 3 256 260 2-s2.0-0034982279 10.1097/00008480-200106000-00008 (Pubitemid 32500280)
28. Wilkesmann A., Ammann R. A., Schildgen O., Eis-Hübinger A. M., Müller A., Seidenberg J., Stephan V., Rieger C., Herting E., Wygold T., Hornschuh F., Groothuis J. R., Simon A., Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatric Infectious Disease Journal 2007 26 6 485 491 2-s2.0-34249777543 10.1097/INF.0b013e31805d01e3 (Pubitemid 46847308)
29. Groothuis J. R., Hoopes J. M., Hemming V. G., Prevention of serious respiratory syncytial virus-related illness-II: immunoprophylaxis. Advances in Therapy 2011 28 2 110 125 2-s2.0-79952533229 10.1007/s12325-010-0101-y
30. Lanari M., Silvestri M., Rossi G. A., Clinical and pharmacological aspects of immunoprophylaxis for respiratory syncytial virus infection in high-risk infants. Current Drug Metabolism 2013 14 2 216 225
31. Geevarghese B., Simões E. A., Antibodies for prevention and treatment of respiratory syncytial virus infections in children. Antiviral Therapy 2012 17 1 201 211
32. Gershwin L. J., Immunology of bovine respiratory syncytial virus infection of cattle. Comparative Immunology, Microbiology & Infectious Diseases 2012 35 3 253 257
33. Prince G. A., Hemming V. G., Horswood R. L., Chanock R. M., Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Research 1985 3 3 193 206 2-s2.0-0022359386 (Pubitemid 16225057)
34. Groothuis J. R., Levin M. J., Rodriguez W., Hall C. B., Long C. E., Kim H. W., Lauer B. A., Hemming V. G., Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. Antimicrobial Agents and Chemotherapy 1991 35 7 1469 1473 2-s2.0-0025775698
35. Meissner H. C., Fulton D. R., Groothuis J. R., Geggel R. L., Marx G. R., Hemming V. G., Hougen T., Snydman D. R., Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrobial Agents and Chemotherapy 1993 37 8 1655 1658 2-s2.0-0027255190 (Pubitemid 23226378)
36. Groothuis J. R., Simoes E. A. F., Levin M. J., Hall C. B., Long C. E., Rodriguez W. J., Arrobio J., Meissner H. C., Fulton D. R., Welliver R. C., Tristram D. A., Siber G. R., Prince G. A., Van Raden M., Hemming V. G., Lehr M. V., Louch G. K., Sondheimer H., Powell K. R., Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. New England Journal of Medicine 1993 329 21 1524 1530 2-s2.0-0027384670 10.1056/NEJM199311183292102 (Pubitemid 23332437)
37. Connor E., Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997 99 1 93 99 2-s2.0-0030959478 10.1542/peds.99.1.93 (Pubitemid 27136610)
38. Groothuis J. R., Nishida H., Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab). Pediatrics International 2002 44 3 235 241 2-s2.0-0036316075 10.1046/j.1442-200X.2002. 01558.x (Pubitemid 34827718)
39. Simoes E. A. F., Sondheimer H. M., Top F.H. J., Meissner H. C., Welliver R. C., Kramer A. A., Groothuis J. R., Lehr M., Fulton D., Hanlon K., Tristram D., Shuff C., Cabalka A., McNamara J., Hoogenhouse N. N., Reuman P., Gessner I. H., Nixon C., Dooley K. J., Keyserling H. L., Hawthorne A., Freeman D. M., Schricker M. E., Miller S., Wald E., Smail K., Feltes T. F., Drutz J., Alexander M.-A., Galindo A., Blumberg D., Acosta B., Crowley D. C., Sandhu N., Smoyer C., Gruber W. C., Graham T., Burger J., Krilov L., Zapalla F., Kleinman C., Baltimore R., Friedman A., Guandalini C., Hohn A., Mason W. H., Hallinan B., Kichuk M. R., Gersony W. M., Saimin L., Lombardi M., Turnbull L., Rowland D., Powell D., Schumer C., Simmons L., Fasules J., Hansen S., Hemming V. G., Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease infants and children with congenital heart disease. Journal of Pediatrics 1998 133 4 492 499 2-s2.0-17944391919 10.1016/S0022- 3476(98)70056-3 (Pubitemid 28465374)
40. Groothuis J. R., Simoes E. A. F., Immunoprophylaxis and immunotherapy: role in the prevention and treatment of respiratory syncytial virus. International Journal of Antimicrobial Agents 1993 2 2 97 104 2-s2.0-0027400931 10.1016/0924-8579(93)90047-9 (Pubitemid 23046366)
41. Oravax 1997 Oravax Company Press Release
42. García-Barreno B., Palomo C., Peñas C., Delgado T., Perez-Breña P., Melero J. A., Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. Journal of Virology 1989 63 2 925 932 2-s2.0-0024505373 (Pubitemid 19057262)
43. Meissner H. C., Groothuis J. R., Rodriguez W. J., Welliver R. C., Hogg G., Gray P. H., Loh R., Simoes E. A. F., Sly P., Miller A. K., Nichols A. I., Jorkasky D. K., Everitt D. E., Thompson K. A., Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease. Antimicrobial Agents and Chemotherapy 1999 43 5 1183 1188 2-s2.0-0032905244 (Pubitemid 29214744)
44. Beeler J. A., Van Wyke Coelingh K., Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. Journal of Virology 1989 63 7 2941 2950 2-s2.0-0024320889 (Pubitemid 19156013)
45. Arbiza J., Taylor G., Lopez J. A., Furze J., Wyld S., Whyte P., Stott E. J., Wertz G., Sullender W., Trudel M., Melero J. A., Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. Journal of General Virology 1992 73 9 2225 2234 2-s2.0-0026738635
46. Huang K., Incognito L., Cheng X., Ulbrandt N. D., Wu H., Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. Journal of Virology 2010 84 16 8132 8140 2-s2.0-77954995414 10.1128/JVI.02699-09
47. Johnson S., Oliver C., Prince G. A., Hemming V. G., Pfarr D. S., Wang S.-C., Dormitzcr M., O'Grady J., Koenig S., Tamura J. K., Woods R., Bansal G., Couchenour D., Tsao E., Hall W. C., Young J. F., Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. Journal of Infectious Diseases 1997 176 5 1215 1224 2-s2.0-16944363559 (Pubitemid 27460986)
48. Kapikian A. Z., Mitchell R. H., Chanock R. M., Shvedoff R. A., Stewart C. E., An epidemiologic study of altered clinical reactivity to Respiratory Syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. American Journal of Epidemiology 1969 89 4 405 421 2-s2.0-0014493282
49. DeVincenzo J. P., Hall C. B., Kimberlin D. W., Sánchez P. J., Rodriguez W. J., Jantausch B. A., Corey L., Kahn J. S., Englund J. A., Suzich J. A., Palmer-Hill F. J., Branco L., Johnson S., Patel N. K., Piazza F. M., Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-Resistant mutants. Journal of Infectious Diseases 2004 190 5 975 978 2-s2.0-4344651091 10.1086/423213 (Pubitemid 39120976)
50. Zhu Q., McAuliffe J. M., Patel N. K., Palmer-Hill F. J., Yang C.-F., Liang B., Su L., Zhu W., Wachter L., Wilson S., MacGill R. S., Krishnan S., McCarthy M. P., Losonsky G. A., Suzich J. A., Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. Journal of Infectious Diseases 2011 203 5 674 682 2-s2.0-79751502456 10.1093/infdis/jiq100
51. Connor E. M., Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998 102 3 I 531 537 2-s2.0-0031683919 10.1542/peds.102.3.531 (Pubitemid 28409250)
52. Wu S.-Y., Bonaparte J., Pyati S., Palivizumab use in very premature infants in the neonatal intensive care unit. Pediatrics 2004 114 5 e554 e556 2-s2.0-16644372782 10.1542/peds.2004-0226 (Pubitemid 41647661)
53. Malley R., Devincenzo J., Ramilo O., Dennehy P. H., Meissner H. C., Gruber W. C., Sanchez P. J., Jafri H., Balsley J., Carlin D., Buckingham S., Vernacchio L., Ambrosino D. M., Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. Journal of Infectious Diseases 1998 178 6 1555 1561 2-s2.0-17344371596 10.1086/314523 (Pubitemid 28558122)
54. Siber G. R., Leombruno D., Leszczynski J., McIver J., Bodkin D., Gonin R., Thompson C. M., Walsh E. E., Piedra P. A., Hemming V. G., Prince G. A., Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. Journal of Infectious Diseases 1994 169 6 1368 1373 2-s2.0-0028277388 (Pubitemid 24164608)
55. Null D. Jr., Pollara B., Dennehy P. H., Steichen J., Sanchez P. J., Givner L. B., Carlin D., Landry B., Top F. H. Jr., Connor E., Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatric Infectious Disease Journal 2005 24 11 1021 1023 2-s2.0-28044466643 10.1097/01.inf.0000183938.33484.bd (Pubitemid 41689617)
56. Feltes T. F., Cabalka A. K., Meissner H. C., Piazza F. M., Carlin D. A., Top F. H. Jr., Connor E. M., Sondheimer H. M., Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. Journal of Pediatrics 2003 143 4 532 540 2-s2.0-0242298724 10.1067/S0022-3476(03)00454-2 (Pubitemid 37352516)
57. Abbott Laboratories,. Data on file. Abbott Laboratories; International Division, Abbott Park; Ill, USA, 2000
58. Sáez-Llorens X., Castaño E., Null D., Steichen J., Sánchez P. J., Ramilo O., Top F. H. Jr., Connor E., Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatric Infectious Disease Journal 1998 17 9 787 791 2-s2.0-0344588819 10.1097/00006454-199809000-00007 (Pubitemid 28475545)
59. Committee on Infectious Disease. American Academy of Pediatrics, Policy statement-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009 124 6 1694 1701
60. Resch B., Michel-Behnke I., Respiratory syncytial virus infections in infants and children with congenital heart disease: update on the evidence of prevention with palivizumab. Current Opinion in Cardiology 2013 28 2 85 91
61. Simões E. A. F., Carbonell-Estrany X., Rieger C. H. L., Mitchell I., Fredrick L., Groothuis J. R., The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. Journal of Allergy and Clinical Immunology 2010 126 2 256 262 2-s2.0-77955926764 10.1016/j.jaci.2010.05.026
62. Faldella G., Alessandroni R., Aquilano G., Vandini S., Lanari M., Silvestri M., Pistorio A., Rossi G. A., Hospitalization for lower respiratory tract disease in preterm infants: effects of prophylaxis with palivizumab. Journal of Chemotherapy 2010 22 1 30 35 2-s2.0-77950169060
63. Sáez-Llorens X., Moreno M. T., Ramilo O., Sánchez P. J., Top F. H. Jr., Connor E. M., Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratoy syncytial virus infection. Pediatric Infectious Disease Journal 2004 23 8 707 712 2-s2.0-4043169059 10.1097/01.inf.0000133165.85909.08 (Pubitemid 39063284)
64. Mejías A., Chávez-Bueno S., Ríos A. M., Aten M. F., Raynor B., Peromingo E., Soni P., Olsen K. D., Kiener P. A., Gómez A. M., Jafri H. S., Ramilo O., Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus Potency. Antimicrobial Agents and Chemotherapy 2005 49 11 4700 4707 2-s2.0-27644485407 10.1128/AAC.49.11.4700-4707.2005 (Pubitemid 41552602)
65. Wu H., Pfarr D. S., Tang Y., An L.-L., Patel N. K., Watkins J. D., Huse W. D., Kiener P. A., Young J. F., Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. Journal of Molecular Biology 2005 350 1 126 144 2-s2.0-20444363121 10.1016/j.jmb.2005.04.049 (Pubitemid 40804737)
66. Wu H., Pfarr D. S., Johnson S., Brewah Y. A., Woods R. M., Patel N. K., White W. I., Young J. F., Kiener P. A., Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract. Journal of Molecular Biology 2007 368 3 652 665 2-s2.0-34047143155 10.1016/j.jmb.2007.02.024 (Pubitemid 46527610)
67. Fernández P., Trenholme A., Abarca K., Griffin M. P., Hultquist M., Harris B., Losonsky G. A., A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatrics 2010 10, article 38 2-s2.0-77954357242 10.1186/1471-2431-10-38
68. Simoes E. A., Carbonell-Estrany X., Losonsky G., Hultquist M., Harris B., Connor E., Phase III trial of motavizumab; an enhanced potency respiratory syncytial virus (RSV)-specific monoclonal antibody for the prevention of serious RSV disease in high risk infants. Acta Paediatrica 2007 96 s456 232 233
69. Abarca K., Jung E., Fernández P., Zhao L., Harris B., Connor E. M., Losonsky G. A., Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. Pediatric Infectious Disease Journal 2009 28 4 267 272 2-s2.0-65649105815 10.1097/INF.0b013e31818ffd03
70. Lanari M., Silvestri M., Rossi G. A., Palivizumab prophylaxis in 'late preterm' newborns. Journal of Maternal-Fetal and Neonatal Medicine 2010 23 3, supplement 53 55 2-s2.0-77957942606 10.3109/14767058.2010.506757
71. Carbonell-Estrany X., Bont L., Doering G., Gouyon J.-B., Lanari M., Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age. European Journal of Clinical Microbiology and Infectious Diseases 2008 27 10 891 899 2-s2.0-53549100990 10.1007/s10096-008-0520-8
72. Lanari M., Silvestri M., Rossi G. A., Respiratory syncytial virus risk factors in late preterm infants. Journal of Maternal-Fetal and Neonatal Medicine 2009 22 3 102 107 2-s2.0-70449372449 10.1080/14767050903194438
73. Weiner L. B., Masaquel A. S., Polak M. J., Mahadevia P. J., Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. Journal of Medical Economics 2012 15 5 997 1018
74. Resch B., Sommer C., Nuijten M. J. C., Seidinger S., Walter E., Schoellbauer V., Mueller W. D., Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Pediatric Infectious Disease Journal 2012 31 1 e1 e8 2-s2.0-84855442866 10.1097/INF.0b013e318235455b
75. Nuijten M. J., Wittenberg W., Cost effectiveness of palivizumab in Spain: an analysis using observational data. European Journal of Health Economics 2010 11 1 105 115 2-s2.0-76649093908 10.1007/s10198-009-0206-x
76. Manzoni P., Paes B., Resch B., Carbonell-Estrany X., Bont L., High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention. Early Human Development 2012 88 2, supplement S34 S41